FDA decisions on Byetta expected in Q1

01/12/2009 | CNNMoney

The FDA may hand down this quarter its decision on a once-weekly formulation of Amylin Pharmaceuticals' Byetta as well updated labeling for the diabetes drug, CEO Daniel Bradbury said. The label changes were prompted by concerns about the risk of pancreatitis.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC